Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author holds a long position in TEM.

← Back to Free Index

TEM

Analysis as of: 2026-11-07

Tempus AI, Inc.

Tempus provides oncology and hereditary diagnostic tests, de-identified clinical data products, and workflow software to physicians, health systems, and biopharma customers.

ai biotech healthcare software

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

A Real Data Flywheel, Still Gated by Reimbursement

The setup is attractive because diagnostics, governed data rights, and workflow placement reinforce one another. The stock can work well from here if higher-margin data, MRD, and verified workflow revenue scale faster than reimbursement and integration friction.

Analysis

Thesis

Tempus can still roughly double equity value by 2031 if it keeps turning reimbursable diagnostics into governed data rights and embedded workflow revenue, then layers MRD, data licensing, and verified clinical execution software on top before reimbursement friction and integration complexity cap the rerating.

Last Economy Alignment

Tempus benefits from cheaper cognition because it does not mainly sell generic AI seats; it owns regulated data rights, diagnostic data generation, and workflow trust points that are harder to copy. The constraint is that reimbursement and data-governance rules still control how fast that flywheel scales.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

2.2x (from 5 most recent analyses)

Reasoning

The upside case is operational, not magical. Tempus already has a real flywheel: diagnostics create proprietary longitudinal data, that data improves products, and those products deepen provider and biopharma usage. If management converts more of that activity into higher-margin data, MRD monitoring, and workflow revenue, the business can earn a better mix and cleaner cash profile. I still do not underwrite a full software multiple because reimbursement, compliance, and integration remain meaningful constraints.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The main risk is not that Tempus lacks assets; it is that its highest-value assets monetize slower than investors expect. Reimbursement controls diagnostics economics, diagnostics fuel the data flywheel, and the next leg of upside depends on integrating Personalis, broadening MRD coverage, and proving that more revenue can come from governed workflow and data products rather than just more tests.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

Q3 2026 results on November 2, 2026 raised full-year revenue guidance to 1600-1605 and kept adjusted EBITDA around 65.
Oncology volume growth accelerated to 32% year over year, while MRD volume reached about 12000 tests, up 300%.
Data & Applications grew 33%, and management quantified roughly 192.5 of five-year revenue tied to the BMS-related agreements disclosed in the shareholder letter.
Personalis had not yet closed as of November 7, 2026; the November 30, 2026 shareholder vote remained the nearest hard gate.

Forecast update

Better execution evidence was partly offset by a richer starting valuation and more explicit dependence on reimbursement and post-close integration.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.53

They do not mainly sell generic AI; they control the lab workflow and the rights to the patient data created there. Each test can be monetized more than once, but healthcare reimbursement and privacy rules still decide how fast that flywheel can spin.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$89.56

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research